Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: An observational long-term study

Dermatology

Volumn 225, Issue 4, 2013, Pages 312-319

  Esposito, Maria ^a   Giunta, Alessandro ^a   Mazzotta, Annamaria ^a   Zangrilli, Arianna ^a   Babino, Graziella ^a   Bavetta, Mauro ^a   Perricone, Roberto ^a   Chimenti, Sergio ^a   Chimenti, Maria Sole ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Adalimumab; Anti TNF alpha; Elderly; Etanercept; Psoriasis

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; ETRETIN; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE;

AGED; ANTIBODY TITER; ARTICLE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DYSPNEA; FEMALE; GLAUCOMA; HEART ATRIUM FIBRILLATION; HUMAN; INJECTION SITE REACTION; LARYNGITIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; SCORING SYSTEM; SIDE EFFECT; STOMACH CANCER; TACHYCARDIA; TONSILLITIS; URINARY TRACT INFECTION; VISUAL ANALOG SCALE; WEIGHT GAIN;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; PAIN MEASUREMENT; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84875211531     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000345623     Document Type: Article

References (20)

1. Christophers E, Mrowietz U: Psoriasis; in Freedberg IM, Eisen AZ, Wolff K, Frank Austen K, Goldsmith LA, Katz SI (eds): Fitzpatrick's Dermatology in General Medicine, ed 6. New York, McGraw-Hill, 2003, pp 407- 427.
2. Naldi L: Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy 2004; 3: 121- 128.
3. Krueger G, Koo J, Lebwohl M, et al: The impact of psoriasis on quality of life; results of a 1998 National Psoriasis Foundation patient- membership survey. Arch Dermatol 2001; 137: 280-284.
4. Gottlieb AB: Novel immunotherapies for psoriasis: clinical research delivers new hope for patients and scientific advances. J Investig Dermatol Symp Proc 2004; 9: 79-83.
5. Mease PJ, Goffe BS, Metz J, et al: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356(9227): 385-390.
6. Leonardi CL, Powers JL, Matheson RT, et al: Etanercept psoriasis study group: etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-2022.
7. Chaudhari U, Romano P, Mulcahy LD, et al: Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial. Lancet 2001; 357(9271): 1842-1847.
8. Papoutsaki M, Chimenti MS, Costanzo A, Talamonti M, Zangrilli A, Giunta A, Bianchi L, Chimenti S: Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics. J Am Acad Dermatol 2007; 57: 269-275.
9. Papoutsaki M, Costanzo A, Chimenti MS, Chimenti S: Adalimumab for the treatment of severe psoriasis and psoriatic arthritis. Expert Opin Biol Ther 2008; 8: 363-370.
10. Ritchlin CT, Kavanaugh A, Gladman DD, et al; Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009; 68: 1387- 1394.
11. Schottelius AJ, Moldawer LL, Dinarello CA, et al: Biology of tumor necrosis factor - implications for psoriasis. Exp Dermatol 2004; 13: 193-222.
12. Taylor WJ, Helliwell PS: Development of diagnostic criteria for psoriatic arthritis: methods and process. Curr Rheumatol Rep 2004; 6: 299-305.
13. Fredriksson T, Pettersson U: Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978; 157: 238-244.
14. Helliwell PS, Fitzgerald O, Mease PJ: Development of composite measures for psoriatic arthritis: a report from the GRAPPA 2010 Annual Meeting. J Rheumatol 2012; 39: 398- 403.
15. Henseler T, Christophers E: Disease concomitance in psoriasis. J Am Acad Dermatol 1995; 32: 982-986.
16. Gisondi P, Girolomoni G: Cardiometabolic comorbidities and the approach to patients with psoriasis. Actas Dermosifiliogr 2009; 100(suppl 2): 14-21.
17. Altobelli E, Petrocelli R, Maccarone M, et al: Risk factors of hypertension, diabetes and obesity in Italian psoriasis patients: a survey on socio-demographic characteristics, smoking habits and alcohol consumption. Eur J Dermatol 2009; 19: 252-256.
18. Migliore A, Bizzi E, Laganà B, et al: The safety of anti-TNF agents in the elderly. Int J Immunopathol Pharmacol 2009; 22: 415-426.
19. Genevay S, Finckh A, Ciurea A, et al: Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a populationbased cohort study. Arthritis Rheum 2007; 57: 679-685.
20. Busquets N, Carmona L, Surís X: Systematic review: safety and efficacy of anti-TNF in elderly patients. Rheumatol Clin 2011; 7: 104- 112.